The association of relative dose-intensity of Platinum-based doublet chemotherapy and the survival outcome in Advanced stage Non-small cell lung cancer

Active, not recruiting

• Conditions: on-small cell lung cancerReceiving Chemotherapy; Non-small cell lung cancer; Chemotherapy, Platinum-based; Dosage Intensity; Progression-Free Survival; Retrospective Cohort Studies; Kaplan-Meier Estimate; Cox Proportional Hazards Models; Thailand

• Registration Number: TCTR20231012010
• Lead Sponsor: Department of Medicine, Maharat Nakhon Ratchasima Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-12
• Study Completion: 2023-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

Patients of both sexes over 18 years old who were diagnosed with advanced-stage non-small cell lung cancer were included. As the first-line treatment, platinum-containing chemotherapy was required for all patients. ECOG Performance must be between 0 and 2.

Exclusion Criteria

Patients having previous malignancies in the preceding five years, excluding basal cell carcinoma and other localized skin cancers, were excluded from the study. Other exclusion criteria comprised patients with platinum-containing chemotherapy during the preceding 12 months or those with uncontrolled brain metastases.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival SoC CT schedule, Death RECIST Version 1.1

Secondary Outcome Measures

Name	Time	Method
Overall survival Death Death status, Date of Death or Date of Last Follow up in Loss F/U case,Overall response rate SoC CT schedule RECIST Version 1.1,Interested Adverse Event SoC visit schedule CTCAE v. 5